Abstract
Purpose:
To explore ‘magnesium myristate’ for its dual functionality as a lubricant and binder in the formulation of tablets.
Methods:
Using (DoE), tablet formulations using magnesium myristate and conventional excipients (magnesium stearate and PVP K30) were developed by wet granulation technique. The prepared granules and formulated tablets were evaluated for pre- and post-compression parameters, respectively.
Results:
Magnesium myristate exhibited excellent flow properties. The optimized formulations containing magnesium myristate exhibited increased hardness and in vitro drug release in comparison to conventional excipients. f2 similarity index for in vitro drug release showed no significant variations with optimized formulations and with the marketed formulations.
Conclusion:
Magnesium myristate shows a promising replacement for conventional excipients as both a lubricant and binder in tablet formulation.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.4155/tde-2023-0101
Author contributions
RD Pockle – Collected data; performed the lab work and prepared the manuscript. RS Masareddy* - designed and monitored the study and approved the manuscript from all co-authors. V Bambulkar – Provided with the novel excipient and guidance for carrying out the project work. R Desai – Provided the facilities to carry out the project work. S Kiran – Helped in drafting of the manuscript.
Acknowledgments
The authors are thankful to Swapnali, Radhika and Sneha, Koel Colors, Pvt. Ltd, Mumbai for providing magnesium myristate as a gift sample. Authors gratefully acknowledge the help of Centaur Pharmaceuticals Pvt. Ltd. Goa for providing Metformin HCl. The authors are grateful to R Desai, Koel Colors, Pvt. Ltd. Mumbai, for providing the infrastructural facilities for completing this work.
Financial disclosure
The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Competing interests disclosure
The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.
Writing disclosure
No writing assistance was utilized in the production of this manuscript.